Drugs / re-directed FAP-specific T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT01722149 | Feb 2015 → Mar 2019 | malignant pleural mesothelioma | University of Zurich | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | re-directed FAP-specific T cells | “Patients will be treated with 1x10e6 re-directed FAP-specific T cells injected in the pleural effusion.” NCT01722149 ↗ |
| Modality | Cell therapy | “CD8 positive T cells will be isolated and re-programmed by retroviral transfer of a chimeric antigen receptor (CAR)” NCT01722149 ↗ |
| Route | Other | “injected in the pleural effusion” NCT01722149 ↗ |
| Target | FAP | “CAR recognizing FAP which serves as target structure in MPM.” NCT01722149 ↗ |